We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYRX icon
151
PUT
CryoPort
CYRX
$761M
$2.19M 0.1%
50,000
-200,000
-80% -$9.53M
NXTC icon
152
NextCure
NXTC
$16.8M
$2.18M 0.1%
16,667
– –
ANAB icon
153
AnaptysBio
ANAB
$1.58B
$2.15M 0.09%
100,000
+50,000
+100% +$1.21M
HROW icon
154
Harrow
HROW
$1.45B
$2.12M 0.09%
308,607
-150,000
-33% -$846K
DCTH icon
155
Delcath Systems
DCTH
$422M
$2.02M 0.09%
112,712
+18,712
+20% +$256K
MBIO icon
156
Mustang Bio
MBIO
$4.32M
$1.99M 0.09%
701
-374
-35% -$894K
ACRS icon
157
Aclaris Therapeutics
ACRS
$726M
$1.94M 0.09%
+300,000
New +$1.27M
DBVT
158
DBV Technologies
DBVT
$799M
$1.9M 0.08%
35,833
+19,360
+118% +$429K
ITCI
159
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.85M 0.08%
58,000
-192,000
-77% -$5.05M
KNSA icon
160
Kiniksa Pharmaceuticals
KNSA
$5.8B
$1.79M 0.08%
101,273
-241,725
-70% -$4.25M
BLCM
161
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.76M 0.08%
+500,000
New +$2.11M
TNGX icon
162
Tango Therapeutics
TNGX
$4.43B
$1.71M 0.08%
149,512
+149,262
+59,705% +$1.57M
OTIC
163
DELISTED
Otonomy, Inc.
OTIC
$1.68M 0.07%
259,337
-175,449
-40% -$797K
CLOV icon
164
Clover Health Investments
CLOV
$2.2B
$1.68M 0.07%
+100,000
New +$1.11M
ATYR
165
aTyr Pharma
ATYR
$47.6M
$1.55M 0.07%
+400,000
New +$1.46M
ACRS icon
166
CALL
Aclaris Therapeutics
ACRS
$726M
$1.53M 0.07%
+235,800
New +$995K
BIIB icon
167
Biogen
BIIB
$30B
$1.4M 0.06%
5,700
+2,700
+90% +$697K
ATXS
168
DELISTED
Astria Therapeutics
ATXS
$1.39M 0.06%
+108,333
New +$1.93M
AUPH icon
169
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.38M 0.06%
100,000
– –
GMDA
170
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.34M 0.06%
+160,000
New +$1.08M
BFLY icon
171
Butterfly Network
BFLY
$1.89B
$1.24M 0.05%
+62,796
New +$804K
RIGL icon
172
Rigel Pharmaceuticals
RIGL
$681M
$1.21M 0.05%
34,553
-35,000
-50% -$1.01M
QTTB icon
173
PUT
Q32 Bio
QTTB
$466M
$1.13M 0.05%
+5,556
New +$1.07M
CMPS
174
Compass Pathways
CMPS
$1.53B
$1.13M 0.05%
23,648
-129,400
-85% -$5.52M
SYRS
175
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.08M 0.05%
+10,000
New +$913K
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.